VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing. For investors and the biotech industry, this move signals a growing shift toward more efficient and ethical preclinical models that may improve the predictive validity of drug development.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). Notably, the company evaluated its lead BiTAC-TCE and bsADC candidates using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Such a dramatic reduction in animal use demonstrates the potential of NAMs to streamline preclinical research while maintaining clinical relevance.
Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and showcasing how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance. The implications are significant: if widely adopted, NAMs could shorten timelines for bringing new cancer therapies to patients, lower costs, and address ethical concerns around animal testing. Moreover, FDA alignment lends regulatory credibility, potentially smoothing the path to clinical trials.
To view the full press release, visit https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA. For more information about VERAXA Biotech, visit VERAXA Biotech (NASDAQ: VRXA).
BioMedWire is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
